Status:
COMPLETED
BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes
Lead Sponsor:
International Antiviral Therapy Evaluation Center
Collaborating Sponsors:
Hoffmann-La Roche
Gilead Sciences
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to assess differences in changes in plasma lipids between patients on saquinavir/ritonavir or atazanavir/ritonavir in combination with tenofovir disoproxil fumarate and em...
Detailed Description
The main objective of the study is to measure changes in blood lipids during 48 weeks of treatment with saquinavir (SQV) / ritonavir (RTV) or atazanavir (ATV) / RTV, in combination with tenofovir (TDF...
Eligibility Criteria
Inclusion
- Providing written informed consent
- HIV-1 infected patients.
- At least 18 years of age.
- Males or non-pregnant, non-lactating females. Women of childbearing age must have a negative urine pregnancy test at screening. All female participants must be encouraged to utilise adequate contraception for the month preceding entry and for the duration of the study.
- Anti-retroviral treatment naive.
- Indication for antiretroviral therapy according to current treatment guidelines.
Exclusion
- CD4 count \> 350 cells/mm3, except in case of symptomatic HIV disease and/or an AIDS-defining illness.
- HIV-2 co infection.
- Use of co-medication with a known pharmacological interaction which precludes the appropriate use of one or more of the study drugs.
- Anticipated non-compliance with the protocol.
- Presence of a newly (within 30 days prior to the time of enrolment) diagnosed HIV-related opportunistic infection or condition which may interfere with the ability to comply with the study.
- Chronic active viral hepatitis or other chronic liver disease, which in the opinion of the investigator is a contraindication for the use of any of the study drugs. Patients who may be considered to have active HBV replication (HBV-surface antigen positive and/or HBV-DNA positive) may be excluded in case the investigator feels that the benefit of starting tenofovir/emtricitabine does not outweigh the risk of a "hepatitis flare" in case tenofovir/emtricitabine would need to be prematurely discontinued for any reason during the trial. Chronic hepatitis C is allowed, provided that treatment for hepatitis C is not anticipated during the study period.
- Women who are pregnant, or have the intention to become pregnant during the study period.
- Clinically relevant laboratory abnormalities: anaemia, thrombocytopenia, leucopenia, elevated liver transaminases, elevated bilirubin, elevated amylase, elevated lipase, which in the opinion of the investigator is a contraindication for the use of any of the study drugs, or any current known clinical or laboratory parameter of ACTG Grade 4 (see Appendix 2). However, asymptomatic Grade 4 abnormalities will be permitted at the discretion of the investigator if deemed clinically appropriate. Abnormalities deemed insignificant by the investigator must be discussed with the sponsor prior to enrolment.
- Significant renal dysfunction (creatinine clearance \[CrCl\] \<60 mL/min) and/or hepatic impairment (aspartate aminotransferase/alanine aminotransferase \[AST/ALT\] \>3 X ULN and/or documented liver cirrhosis)
- Note: The site will calculate each patient's CrCl using the Cockcroft-Gault formula as shown below:
- CrCl = \[140 - age (yr)\] × weight (kg) × constant 72 × serum creatinine (Cr) (mg/dL) where, constant = 1 for men and 0.85 for women.
- Use of nephrotoxic agents which in the opinion of the investigator are a contraindication for the use of tenofovir disoproxil fumarate and any other of the study drugs.
- Patients who have received within 4 weeks prior to entry, or who have an anticipated need for treatment with radiation therapy or cytotoxic chemotherapeutic agents during the protocol study period.
- Patients who have taken any investigational drug 30 days prior to the start of the study.
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2008
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00389402
Start Date
July 1 2006
End Date
July 1 2008
Last Update
June 11 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Academic Medical Centre, University of Amsterdam
Amsterdam, Netherlands, 1105 AZ